Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy.
Plasma concentrations of tumor necrosis factor-alpha (TNF-alpha) were measured in 10 outpatients with panic disorder, twice (at a 48-h interval) before and twice on days 30-32 of treatment with alprazolam (2-2.5 mg/day), and twice in 10 age- and sex-matched healthy controls. TNF-alpha concentrations did not differ in patients and control subjects, either before therapy or at days 30-32 of therapy. In five patients before therapy, and in three of them after therapy, TNF-alpha values were higher than the maximal concentrations of the cytokine in controls.
Brambilla
F
F
Dipartimento di Scienze Neuropsichiche, Istituto Scientifico Ospedale S. Raffaele, Milano, Italy.
Bellodi
L
L
Perna
G
G
D000328:Adult; D000379:Agoraphobia / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000525:Alprazolam / Q000009:adverse effects / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012016:Reference Values; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D014151:Anti-Anxiety Agents; D014409:Tumor Necrosis Factor-alpha; D000525:Alprazolam